4:10 PM
Aug 07, 2017
 |  BC Extra  |  Company News

Investor urges Acorda to sell

In a letter, Scopia Capital Management LP urged the board of Acorda Therapeutics Inc. (NASDAQ:ACOR) to consider a sale of the company. Scopia owns 16.5% of Acorda.

Following a March court ruling that drastically shortened U.S. patent protection for Acorda's multiple sclerosis drug Ampyra dalfampridine to 2018 from 2027, Scopia wrote it now anticipates Acorda will revert...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >